TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02633098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo PO OD for 14 days prior to colorectal resection surgery
Study: NCT03526848
Drug: 3BNC117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3BNC117
Study: NCT03603626
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hour before surgery
Study: NCT01967940
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet administered orally once daily with food
Study: NCT01967940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to match TAF administered orally once daily with food
Study: NCT01967940
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg STR administered orally once daily with food
Study: NCT01967940
Drug: Current failing ARV regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue taking their current ARV regimen as prescribed in Part 1.
Study: NCT01419964
Drug: Group 01
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH24
Study: NCT01419964
Drug: Group 02
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00870740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC injection
Study: NCT02015260
Drug: Topical NO
Normalized name: thickening agent, topical no.1 TOPICAL LIQUID (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varying doses of sodium nitrite and citric acid co-applied to warts
Study: NCT02015260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01882166
Drug: fostimon
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05129644
Drug: P1101 (24 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
Study: NCT05129644
Drug: P1101 (48 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
Study: NCT05129644
Drug: P1101 (90 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
Study: NCT05129644
Drug: P1101 (180 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
Study: NCT05129644
Drug: P1101 (225 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
Study: NCT05129644
Drug: P1101 (270 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
Study: NCT00100971
Drug: autologous tumor cell vaccine
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00100971
Drug: therapeutic autologous dendritic cells
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03606902
Drug: Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
Study: NCT04516447
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT04516447
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) is an approved drug
Study: NCT02718404
Drug: MR contrast media and medications
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
Study: NCT02976909
Drug: Paclitaxel+Cisplatin+5fluorouracil
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
Study: NCT00759941
Drug: Placebo eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop three times a day in both eyes for 3 months
Study: NCT01723384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01054443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00671736
Drug: Moli1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,5 ml inhalation solution, 8 weeks treatment period
Study: NCT00671736
Drug: Moli1901 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,5 ml placebo solution, 8 weeks treatment period
Study: NCT03827096
Drug: Suspension of human autologous MSC 3P in 1.5 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
Study: NCT00984386
Drug: Zesteem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
Study: NCT00873483
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
Study: NCT00984386
Drug: Zesteem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
Study: NCT00984386
Drug: Zesteem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
Study: NCT00984386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal placebo, 100μl administered once before punch biopsy
Study: NCT02140268
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
Study: NCT00288431
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered at 60 mg/m2 intravenously every 3 weeks
Study: NCT01061073
Drug: spasfon
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03783312
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Study: NCT03783312
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Study: NCT04215731
Drug: Induction chemotherpay with FOLFOX
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
Study: NCT04062097
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: This drug group includes the active substances phenprocoumon and warfarin.
Study: NCT03012503
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
Study: NCT00905164
Drug: Topamax® Capsules, 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topamax® Capsules, 2 x 25 mg
Study: NCT01173666
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
Study: NCT04396756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00091949
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an inactive substance
Study: NCT00269217
Drug: niacin (+) laropiprant (+) simvastatin
Normalized name: niacin / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment 12 Weeks
Study: NCT00269217
Drug: Comparator: simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment 12 Weeks
Study: NCT01632696
Drug: I-124 PGN650 for PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
Study: NCT01105481
Drug: Placebo add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
Study: NCT03347721
Drug: Lubricant Gel
Normalized name: Surgilube Lubricant Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricating gel
Study: NCT02083900
Drug: Hydrocolloid Dressing (DuoDERM CGF)
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
Study: NCT03780673
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for 12 months
Study: NCT03666663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Saline using the Sphenocath device- cleared by FDA
Study: NCT01841099
Drug: Placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided by Ferring Pharma
Study: NCT01704716
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
Study: NCT01704716
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is given during Induction Treatment (R3 arm modified N7)
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT02231086
Drug: Standard adjuvant systemic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT01004822
Drug: CVX-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT00547404
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
Study: NCT00551811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be intended to be administered orally.
Study: NCT00223158
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match grazoprevir tablets to maintain dose blinding
Study: NCT00628667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03081117
Drug: Insulin, intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin administered by specialized, non-commercial intranasal drug delivery device
Study: NCT03081117
Drug: Placebo, intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution administered by specialized, non-commercial intranasal drug delivery device
Study: NCT04003467
Drug: Placebo of EBP05
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT01696110
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin monotherapy
Study: NCT04057326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets/time, 3 times daily,Oral Administration.
Study: NCT02201394
Drug: Aspirin maintenance dose
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 81 mg once daily x 7 days
Study: NCT00632814
Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
Study: NCT00632814
Drug: rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
Study: NCT00632814
Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for patients in this group
Study: NCT01334502
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01334502
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT03980080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle study drug
Study: NCT01674010
Drug: ELND005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03159455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration - 28 days
Study: NCT01697670
Drug: Photodynamic therapy with Gliolan
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
Study: NCT00904605
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
Study: NCT02426164
Drug: bupivacaine HCl, morphine, epinephrine, methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
Study: NCT03027609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo (+ SOC antibiotics)
Study: NCT01197118
Drug: chemotherapy alone following radical resection
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1\~5, i.v.; leucovorin, 200 mg/m2/day on day 1\~5, i.v.; every 21 days repeated, for 6 cycles.
Study: NCT00918255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection using prefilled syringe containing 0.8 milliliters
Study: NCT04273776
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avicel
Study: NCT00813241
Drug: celecoxib reference formulation
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg single oral dose of celecoxib tablets
Study: NCT00813241
Drug: celecoxib test formulation A1
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg single oral dose of celecoxib A1 formulation tablets
Study: NCT00813241
Drug: celecoxib test formulation B2
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg single oral dose of celecoxib B2 formulation tablets
Study: NCT00813241
Drug: celecoxib test formulation C1
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single oral dose of celecoxib Cl formulation tablets
Study: NCT00408317
Drug: Ultrase® MT20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
Study: NCT00408317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
Study: NCT02909400
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04098991
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
Study: NCT04237597
Drug: CSG452
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSG452 tablets
Study: NCT03169127
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
Study: NCT02641691
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02641691
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00403429
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03057769
Drug: Papillary epinephrine spraying
Normalized name: epinephrine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
Study: NCT03057769
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Study: NCT01469416
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg PO x 1
Study: NCT01605708
Drug: REGN846
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1
Study: NCT00960882
Drug: DMMET-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1050.6 mg daily for 30 days